Cara Therapeutics (NASDAQ:CARA) Now Covered by StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a report issued on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Cara Therapeutics Stock Up 0.2 %

Shares of CARA stock opened at $0.26 on Friday. Cara Therapeutics has a 52 week low of $0.24 and a 52 week high of $1.31. The firm has a 50 day moving average of $0.29 and a two-hundred day moving average of $0.33. The stock has a market capitalization of $14.37 million, a PE ratio of -0.15 and a beta of 0.64.

Hedge Funds Weigh In On Cara Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Disciplined Growth Investors Inc. MN lifted its stake in Cara Therapeutics by 6.6% in the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock worth $499,000 after acquiring an additional 120,660 shares during the last quarter. FMR LLC increased its position in shares of Cara Therapeutics by 18.5% in the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 32,789 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Cara Therapeutics in the 3rd quarter valued at $29,000. 44.66% of the stock is owned by institutional investors and hedge funds.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.